[go: up one dir, main page]

WO2019155151A3 - Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations - Google Patents

Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations Download PDF

Info

Publication number
WO2019155151A3
WO2019155151A3 PCT/FR2019/050245 FR2019050245W WO2019155151A3 WO 2019155151 A3 WO2019155151 A3 WO 2019155151A3 FR 2019050245 W FR2019050245 W FR 2019050245W WO 2019155151 A3 WO2019155151 A3 WO 2019155151A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor subtype
endothelin receptor
antibody against
relates
present
Prior art date
Application number
PCT/FR2019/050245
Other languages
English (en)
Other versions
WO2019155151A2 (fr
Inventor
Didier Boquet
Amaury HERBET
Frédéric Ducancel
Narciso COSTA
Jean-Yves Couraud
Jean-Philippe Hugnot
Original Assignee
Commissariat A L'energie Atomique Et Aux Energies Alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat A L'energie Atomique Et Aux Energies Alternatives filed Critical Commissariat A L'energie Atomique Et Aux Energies Alternatives
Priority to US16/967,763 priority Critical patent/US12084505B2/en
Priority to JP2020542857A priority patent/JP7456930B2/ja
Priority to EP19744751.9A priority patent/EP3735428A2/fr
Publication of WO2019155151A2 publication Critical patent/WO2019155151A2/fr
Publication of WO2019155151A3 publication Critical patent/WO2019155151A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre le sous-type A des récepteurs aux endothélines notamment monoclonaux, un fragment ou un dérivé de ceux-ci. La présente invention concerne également l'utilisation thérapeutique, diagnostique ou comme outil de recherche d'un tel anticorps dans le domaine des cancers et notamment du glioblastome.
PCT/FR2019/050245 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations WO2019155151A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/967,763 US12084505B2 (en) 2018-02-07 2019-02-04 Antibody against the endothelin receptor subtype A, and uses thereof
JP2020542857A JP7456930B2 (ja) 2018-02-07 2019-02-04 エンドセリン受容体サブタイプａに対する抗体及びその使用
EP19744751.9A EP3735428A2 (fr) 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1851026A FR3077574B1 (fr) 2018-02-07 2018-02-07 Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
FR1851026 2018-02-07

Publications (2)

Publication Number Publication Date
WO2019155151A2 WO2019155151A2 (fr) 2019-08-15
WO2019155151A3 true WO2019155151A3 (fr) 2019-12-12

Family

ID=62017513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2019/050245 WO2019155151A2 (fr) 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations

Country Status (5)

Country Link
US (1) US12084505B2 (fr)
EP (1) EP3735428A2 (fr)
JP (1) JP7456930B2 (fr)
FR (1) FR3077574B1 (fr)
WO (1) WO2019155151A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165823A2 (fr) * 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095353A2 (fr) * 2006-02-14 2007-08-23 Geisinger Clinic Récepteurs gpcr utilisés comme cibles pour l'angiogenèse
CN103728454A (zh) * 2012-10-10 2014-04-16 上海博戍生物科技有限公司 基于表位抗原肽的抗内皮素受体a抗体酶联免疫检测方法及其在ctd-pah中的应用
CA2971491A1 (fr) * 2014-12-05 2017-06-08 Gmax Biopharm Llc. Anticorps de liaison au recepteur de l'endotheline humaine et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2008280266A (ja) * 2007-05-09 2008-11-20 Sekisui Chem Co Ltd モノクローナル抗体
FR2965810B1 (fr) 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
FR3053042B1 (fr) 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095353A2 (fr) * 2006-02-14 2007-08-23 Geisinger Clinic Récepteurs gpcr utilisés comme cibles pour l'angiogenèse
CN103728454A (zh) * 2012-10-10 2014-04-16 上海博戍生物科技有限公司 基于表位抗原肽的抗内皮素受体a抗体酶联免疫检测方法及其在ctd-pah中的应用
CA2971491A1 (fr) * 2014-12-05 2017-06-08 Gmax Biopharm Llc. Anticorps de liaison au recepteur de l'endotheline humaine et leur utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. HERBET ET AL: "Antibodies Targeting Human Endothelin-1 Receptors Reveal Different Conformational States in Cancer Cells", PHYSIOLOGICAL RESEARCH., 6 May 2018 (2018-05-06), CZ, pages S257 - S264, XP055635431, ISSN: 0862-8408, DOI: 10.33549/physiolres.933848 *
IRANI SOUSSAN ET AL: "A review of the profile of endothelin axis in cancer and its management", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 89, no. 2, 4 September 2013 (2013-09-04), pages 314 - 321, XP028817538, ISSN: 1040-8428, DOI: 10.1016/J.CRITREVONC.2013.08.011 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *

Also Published As

Publication number Publication date
JP7456930B2 (ja) 2024-03-27
FR3077574B1 (fr) 2022-04-01
EP3735428A2 (fr) 2020-11-11
US20220089755A1 (en) 2022-03-24
US12084505B2 (en) 2024-09-10
JP2021513345A (ja) 2021-05-27
FR3077574A1 (fr) 2019-08-09
WO2019155151A2 (fr) 2019-08-15

Similar Documents

Publication Publication Date Title
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
MX2018008592A (es) Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
AU2015347015A8 (en) Antibody drug conjugates
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
WO2020121195A8 (fr) Anticorps trem2 et leurs utilisations
MX2017001446A (es) Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso.
WO2017004026A8 (fr) Anticorps anti-cd 123 et conjugués et dérivés correspondants
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2017001599A (es) Anticuerpos novedosos y sus usos.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
NZ604003A (en) Monoclonal antibodies against her2
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
WO2014163714A3 (fr) Conjugués médicament-anticorps
EP3873940A4 (fr) Anticorps anti-ctla4, fragments d'anticorps, leurs immunoconjugués et utilisations associées
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP3705494A3 (fr) Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
ZA202008095B (en) Humanized antibodies against psma
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020542857

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019744751

Country of ref document: EP

Effective date: 20200806

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19744751

Country of ref document: EP

Kind code of ref document: A2